Company Overview

GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Lyell Immunopharma, Inc.; Novartis; Sanofi SA; Surface Oncology; Progentec Diagnostics, Inc.; Alector, Inc.; and CureVac AG., as well as strategic partnership with IDEAYA Biosciences, Inc. and Vir Biotechnology, Inc. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.

  • Name

    GSK plc

  • CEO

    Ms. Emma Natasha Walmsley

  • Website

    www.gsk.com

  • Sector

    Pharmaceuticals

  • Year Founded

    1715

Profile

  • Market Cap

    £67.36B

  • EV

    £80.72B

  • Shares Out

    4,078.96M

  • Revenue

    £31.45B

  • Employees

    70,212

Margins

  • Gross

    72.78%

  • EBITDA

    34.93%

  • Operating

    28.58%

  • Pre-Tax

    15.96%

  • Net

    12.83%

  • FCF

    19.54%

Returns (5Yr Avg)

  • ROA

    9.71%

  • ROTA

    -58.61%

  • ROE

    45.64%

  • ROCE

    15.77%

  • ROIC

    11.14%

Valuation (TTM)

  • P/E

  • P/B

  • EV/Sales

  • EV/EBITDA

  • P/FCF

  • EV/Gross Profit

Valuation (NTM)

  • Price Target

    £19.68

  • P/E

  • PEG

  • EV/Sales

  • EV/EBITDA

  • P/FCF

Financial Health

  • Cash

    £2,983M

  • Net Debt

    £13.96B

  • Debt/Equity

    1.23

  • EBIT/Interest

    13.55

Growth (CAGR)

  • Rev 3Yr

    3.48%

  • Rev 5Yr

    -0.2%

  • Rev 10Yr

    2.49%

  • Dil EPS 3Yr

    -3.45%

  • Dil EPS 5Yr

    -2.51%

  • Dil EPS 10Yr

    -2.12%

  • Rev Fwd 2Yr

    4.92%

  • EBITDA Fwd 2Yr

    0.21%

  • EPS Fwd 2Yr

    6.56%

  • EPS LT Growth Est

    8.4%

Dividends

  • Yield

  • Payout

    60.48%

  • DPS

    £0.6

  • DPS Growth 3Yr

    -15.66%

  • DPS Growth 5Yr

    -9.71%

  • DPS Growth 10Yr

    -4.98%

  • DPS Growth Fwd 2Yr

    4.99%

LSE:GSK